Which medication class helps prolong the endogenous action of GLP-1?

The class of medications that helps to prolong the endogenous action of GLP-1 is the DPP-4 inhibitors. These drugs inhibit the enzyme Dipeptidyl Peptidase-4 (DPP-4), which is responsible for the rapid degradation of GLP-1 (Glucagon-Like Peptide-1). By blocking this enzyme, DPP-4 inhibitors increase the concentration and duration of action of GLP-1 in the bloodstream.

GLP-1 is an incretin hormone that plays a crucial role in glucose metabolism by stimulating insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying. Therefore, by prolonging the action of GLP-1, DPP-4 inhibitors aid in better glucose control in patients with type 2 diabetes.

Other medication classes mentioned do not directly influence the action of GLP-1. Biguanides, such as metformin, primarily work by decreasing hepatic glucose production and improving insulin sensitivity, but they do not have a direct effect on GLP-1 levels. Sulfonylureas stimulate insulin secretion from the pancreas but do not impact GLP-1 degradation or action. Thiazolidinediones improve insulin sensitivity in peripheral tissues